These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 37658556

  • 1. Radiopharmaceuticals used for diagnosis and therapy of NETs.
    Papachristou M.
    Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
    [Abstract] [Full Text] [Related]

  • 2. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
    Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP.
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
    [Abstract] [Full Text] [Related]

  • 3. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
    Kjaer A, Knigge U.
    Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA, Papadogias D, Makras P, Grossman AB.
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP.
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [Abstract] [Full Text] [Related]

  • 9. Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.
    Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP.
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP.
    Acc Chem Res; 2009 Jul 21; 42(7):873-80. PubMed ID: 19445476
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of radiolabelled somatostatin analogues (90Y-DOTATOC and 177Lu-DOTATATE) in patients with metastatic neuroendocrine tumours: a single centre experience in Mexico.
    Medina-Ornelas SS, García-Pérez FO.
    Rev Esp Med Nucl Imagen Mol; 2017 Jul 21; 36(3):166-174. PubMed ID: 27890514
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy.
    Kennedy J, Chicheportiche A, Keidar Z.
    Semin Nucl Med; 2022 Mar 21; 52(2):229-242. PubMed ID: 34911637
    [Abstract] [Full Text] [Related]

  • 16. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?
    Briganti V, Cuccurullo V, Di Stasio GD, Mansi L.
    Curr Radiopharm; 2019 Mar 21; 12(2):156-170. PubMed ID: 30827276
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.
    Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, Núñez R.
    J Nucl Med; 2022 Sep 21; 63(9):1326-1333. PubMed ID: 34992153
    [Abstract] [Full Text] [Related]

  • 19. 225Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.
    King AP, Gutsche NT, Raju N, Fayn S, Baidoo KE, Bell MM, Olkowski CS, Swenson RE, Lin FI, Sadowski SM, Adler SS, Thiele NA, Wilson JJ, Choyke PL, Escorcia FE.
    J Nucl Med; 2023 Apr 21; 64(4):549-554. PubMed ID: 36396453
    [Abstract] [Full Text] [Related]

  • 20. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
    Mirzaei S, Bastati B, Lipp RW, Knoll P, Zojer N, Ludwig H.
    Oncology; 2011 Apr 21; 80(5-6):326-9. PubMed ID: 21791941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.